Entrada Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
186.52 |
46.77 |
25.23 |
28.21 |
304.77 |
439.77 |
| Przychód Δ r/r |
0.00% |
-74.92% |
-46.06% |
11.81% |
980.32% |
44.30% |
| Przychód (min) |
184.74 |
36.29 |
18.97 |
21.21 |
229.17 |
330.69 |
| Przychód (max) |
189.23 |
58.50 |
32.75 |
36.62 |
395.65 |
570.90 |
| EBITDA (średnia) |
120.14 |
30.13 |
16.25 |
18.17 |
196.30 |
283.26 |
| EBIT (średnia) |
119.32 |
29.92 |
16.14 |
18.05 |
194.96 |
281.32 |
| EBIT % |
63.97% |
63.97% |
63.97% |
63.97% |
63.97% |
63.97% |
| Zysk netto (średni) |
40.89 |
-123.30 |
-160.64 |
-157.67 |
-185.38 |
-195.02 |
| Zysk netto % |
21.92% |
-263.61% |
-636.69% |
-558.91% |
-60.83% |
-44.35% |
| EPS (średnia) |
1.05 |
-3.16 |
-4.25 |
-3.92 |
-4.75 |
-5.00 |
| Liczba analityków (Przychody) |
5 |
4 |
3 |
1 |
1 |
1 |
| Liczba analityków (EPS) |
4 |
3 |
3 |
1 |
1 |
1 |
| symbol |
TRDA |
TRDA |
TRDA |
TRDA |
TRDA |
TRDA |